Skip to content
biotechnology hero image
biotechnology hero image

Biotechnology

Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.

Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.

We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.

We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.

News & insights

Publications: 30 MARCH 2020

China’s life sciences industry remains opportune despite Covid-19 coronavirus

While the novel Covid-19 coronavirus is at the top of the agenda for businesses around the world, and for good reason, it is creating challenges for medical and healthcare systems and signalling fundamental change across the life sciences industry. 

Read more
coronavirus

Publications: 16 MARCH 2020

Coronavirus - what is the current situation in Germany?

In order to contain the Coronavirus the German federal states as well as the German government have put strict measures into place. Schools and kindergartens have been closed as well as borders to most neighbouring states for private travel. In order to mitigate the economic consequences, the German government announced a comprehensive package of measures.

Read more

Publications: 19 FEBRUARY 2020

Phase One Sino–U.S. trade agreement and the pharmaceutical industry

On 16 January 2020, China and the United States signed the Economic and Trade Agreement between the Government of the People’s Republic of China and the Government of the United States of America (the Phase One Trade Agreement).

Read more
A person holding a test tube containing cannabis leaves

Publications: 29 NOVEMBER 2019

Flying high

As more countries liberalise their cannabis policies, there has been a rapid increase in the number of registered IP rights as competitors seek to establish their places in the market.

Read more

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2020

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.